GSK Expands Share Buyback Program with Latest Purchase

The latest update is out from GlaxoSmithKline ( (GB:GSK) ).

GSK has announced the purchase of 15,858 of its own ordinary shares as part of its ongoing buyback program, conducted through Merrill Lynch International. This transaction, which is part of a non-discretionary agreement made in June 2025, aims to manage the company’s capital structure and potentially enhance shareholder value. Following this purchase, GSK holds 247,464,844 shares in treasury, with a total of 4,067,938,124 shares in issue, excluding treasury shares. The move reflects GSK’s strategic financial management and impacts its voting rights, which now stand at 6.08% for treasury shares.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GlaxoSmithKline’s strong financial performance and positive earnings call are the most significant factors driving the score. The company’s strategic focus on specialty medicines and shareholder returns, combined with a reasonable valuation and positive technical indicators, support a favorable outlook. Challenges in vaccine sales and regulatory headwinds are noted but are balanced by the company’s innovation and growth initiatives.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GlaxoSmithKline (GSK) is a global healthcare company that operates in the pharmaceutical industry, focusing on the development and production of vaccines, medicines, and consumer healthcare products. The company is known for its commitment to innovation and improving global health outcomes.

Average Trading Volume: 8,197,784

Technical Sentiment Signal: Strong Buy

Current Market Cap: £59.31B

See more data about GSK stock on TipRanks’ Stock Analysis page.